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ABSTRACT
Medulloblastoma is the most common malignant brain cancer of childhood. 
Further understanding of tumorigenic mechanisms may define new therapeutic 
targets. Geminin maintains genome fidelity by controlling re-initiation of DNA 
replication within a cell cycle. In some contexts, Geminin inhibition induces 
cancer-selective cell cycle arrest and apoptosis and/or sensitizes cancer cells 
to Topoisomerase IIα inhibitors such as etoposide, which is used in combination 
chemotherapies for medulloblastoma. However, Geminin’s potential role in 
medulloblastoma tumorigenesis remained undefined. Here, we found that Geminin 
is highly expressed in human and mouse medulloblastomas and in murine granule 
neuron precursor (GNP) cells during cerebellar development. Conditional Geminin 
loss significantly enhanced survival in the SmoA1 mouse medulloblastoma model. 
Geminin loss in this model also reduced numbers of preneoplastic GNPs persisting at 
one postnatal month, while at two postnatal weeks these cells exhibited an elevated 
DNA damage response and apoptosis. Geminin knockdown likewise impaired human 
medulloblastoma cell growth, activating G2 checkpoint and DNA damage response 
pathways, triggering spontaneous apoptosis, and enhancing G2 accumulation of cells 
in response to etoposide treatment. Together, these data suggest preneoplastic and 
cancer cell-selective roles for Geminin in medulloblastoma, and suggest that targeting 
Geminin may impair tumor growth and enhance responsiveness to Topoisomerase 
IIα-directed chemotherapies. 
INTRODUCTION
Initiation of DNA replication is a tightly controlled 
process, involving formation of pre-replication complexes 
(pre-RCs) on sites in the genome [1-3]. After initiation 
of DNA replication, several convergent pathways 
restrict additional pre-RC formation, limiting genome 
duplication to once per cell division [4-9]. The primary 
target of this regulation in most metazoan cells is Cdt1, 
which is inactivated by mechanisms involving either Cdt1 
proteolysis or inhibitory interaction with the nucleoprotein 
Geminin (Gmnn) [1, 2, 4, 7, 9]. Gmnn-mediated inhibition 
of Cdt1 becomes active during S/G2 to prevent reinitiation 
of DNA replication within a cell cycle, while Gmnn 
proteolysis during mitosis enables initiation of a new 
round of replication in the subsequent cell cycle [9]. 
Cells bypassing these controls accumulate DNA damage, 
including >4N DNA content and stalled replication forks. 
This can trigger G2 checkpoint arrest, which is frequently 
followed by apoptosis. 
Prior work comparing Gmnn requirements in 
multiple cancer- and non-cancer-derived cell lines 
suggested that some cancer cell lines are particularly 
dependent upon levels of Gmnn activity and selectively 
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sensitive to Gmnn inhibition, exhibiting re-replication, 
G2 checkpoint activation, and apoptosis under conditions 
where Gmnn-deficient non-cancer cell lines are unaffected 
[10]. This cancer cell sensitivity to Gmnn loss may 
involve greater relative ability of non-cancer cell lines 
to use alternate molecular mechanisms to control Cdt1 
activity by proteolysis, and/or relative over-expression of 
Cdt1 and pre-RC proteins in many cancer cell contexts 
[10, 11]. Based upon these results, it has been proposed 
that small molecule inhibitors directed against Gmnn may 
have utility as selective anticancer agents [10, 12].
Gmnn is over-expressed in many tumor types, 
with high expression frequently serving as a diagnostic 
criterion for aggressiveness and poor prognosis [13-21]. 
In addition to a role in maintaining genome fidelity, Gmnn 
is required for several aspects of embryonic development, 
and can control embryonic gene expression through 
interactions with chromatin regulatory complexes [22-
35]. For example, Gmnn promotes neural fate acquisition 
of embryonic stem cells [30, 36], while loss of Gmnn 
function in the forming central nervous system from 
embryonic day 8.0 (E8.0) in conditional mouse models 
results in neural tube defects, at least in part through 
failure to activate expression of genes that promote neural 
tube patterning and neuronal differentiation [29]. 
Given Gmnn’s potential to selectively inhibit DNA 
replication in other types of cancer, we hypothesized 
that Gmnn could potentially modulate tumorigenesis in 
medulloblastoma, the most common malignant pediatric 
brain tumor and the leading cause of cancer-related death 
in children. Medulloblastoma accounts for ~20% of all 
malignant brain cancers of childhood [37]. Multi-modal 
treatment including tumor resection, radiotherapy, and 
adjuvant chemotherapy have improved long term event-
free survival for average risk patients, but outcomes 
are inferior in children of <3 years or in patients with 
tumor recurrence [37-39]. Further development of 
targeted treatments is likely to emerge from an improved 
understanding of the molecular mechanisms underlying 
this disease. Therefore, here we used both mouse animal 
and human cell models to study whether Gmnn could act 
as a modifier of medulloblastoma tumorigenesis and to 
begin to elucidate some of the underlying mechanisms. 
RESULTS
Geminin is highly expressed in human and mouse 
medulloblastoma 
As Gmnn inhibition selectively impaired the growth 
of several cancer cell lines under conditions where normal/
non-cancer lines were not affected [10], we hypothesized 
that Gmnn inhibition might represent a therapeutic target 
in medulloblastoma. Using publicly available data, 
we found that Gmnn expression is elevated in human 
medulloblastomas, relative to normal cerebellum (Figure 
1A). Human tumors with high Gmnn expression levels 
also exhibit high levels of expression of genes associated 
with the cell cycle, DNA damage/repair, and components 
of the pre-replication complex (e.g. Ccnb1/b2, Cenpe/h, 
Mcm6, Orc1/6)(Figure 1B-1C; Supplementary Table 
1). Gmnn expression was most strongly anti-correlated 
with terms associated with differentiated neural cells 
(transmission of nerve impulse, neuropeptide signaling, 
voltage-gated channel). All genes positively correlated 
with Gmnn in human medulloblastoma and correlated and 
anti-correlated GO terms are in Supplementary Tables 1-3. 
These data are consistent with Gmnn being most highly 
expressed in rapidly proliferating cells of the tumor and 
anti-correlated with differentiated cells or brain regions. 
Likewise, in a murine medulloblastoma model (SmoA1), 
Gmnn and the proliferative cell marker Ki-67 were both 
strongly expressed in tumor tissue, while neither marker 
was expressed in adjacent normal brain tissue (Figure 1D).
Based upon genomic sequencing and expression 
analysis, medulloblastomas have been divided into four 
major molecular subgroups: Wnt, Sonic Hedgehog (Shh), 
Group 3, and Group 4 [40-43]. We therefore examined 
Gmnn expression levels in human medulloblastomas based 
on molecular and histological subtypes, sex, and several 
other criteria (presence of a β-catenin mutation, staging, 
time of diagnosis), using two medulloblastoma expression 
datasets. No subtype or sex-dependent differences in 
Gmnn levels were seen, with the exception of lower 
Gmnn levels in Wnt subtype tumors with monosomy 6, 
consistent with the location of Gmnn on chromosome 6 
(Supplementary Figure 1). 
Geminin deficiency enhances survival in the 
SmoA1 medulloblastoma model 
About 30% of human medulloblastomas exhibit 
constitutive Shh pathway activation [44], resulting from 
either inactivating mutations in the negative regulators 
Patched1 (Ptch1) or Suppressor of Fused (Sufu), or 
from activating mutations in the signal transducing 
receptor Smoothened (Smo) or amplification of the 
Gli2 transcription factor [42, 45-47]. Formation of these 
tumors involves abnormal development of granule 
neuron precursors (GNPs) [48, 49]. Granule neurons are 
the most abundant cerebellar neurons and develop from 
committed GNPs, which migrate over the surface of the 
developing cerebellum to form the external granule layer 
(EGL) and undergo major expansion in the EGL during 
the first two postnatal weeks of development in the mouse 
[49, 50]. After this, they exit the cell cycle, differentiate, 
and migrate through the adjacent Purkinje cell layer to 
establish the internal granule layer (IGL) [48, 49].
In the mouse, Gmnn was previously shown to be 
expressed in proliferating embryonic neural progenitors 
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and adult neural stem cells, with downregulation of 
Gmnn expression accompanying the transition from 
progenitor to post-mitotic neuron [29, 51]. We examined 
its expression in the developing cerebellum, and found 
that Gmnn is highly expressed by GNPs in the EGL of 
the murine neonatal cerebellum at postnatal day 5 (P5), 
with expression overlapping Ki67, which marks all 
proliferating cells (Figure 2A). As conditional loss of 
Gmnn in the forming neural plate from ~E8.0 in the mouse 
resulted in neural tube defects [29], we assessed later 
neurodevelopmental requirements here by performing 
Nestin-Cre-mediated conditional Gmnn excision. B6.Cg-
Tg(Nes-Cre)1Kln/J (Jax 003771; hereafter Nes-Cre) mice 
express Cre recombinase under control of the rat nestin 
promoter and enhancer, predominantly in neural stem 
and progenitor cells of the central and peripheral nervous 
system (CNS/PNS) from embryonic day 10.5. Using this 
line, Gmnn protein levels in the CNS were previously 
shown to be strongly reduced by E14.5 [52]. Congruent 
with prior work [52], Nes-Cre; Gmnnfl/fl mice developed 
into normal, fertile adults. As described in detail below 
(Supplementary Figure 10), we further subjected these 
animals to a battery of behavioral assays and found that 
they exhibited no motor, cognitive, or other detectable 
behavioral abnormalities, which was consistent with 
prior work demonstrating a lack of neural stem cell or 
neurogenesis defects in this model [52]. Therefore, we 
used this model to test whether Gmnn deficiency could 
modify medulloblastoma formation or progression, by 
combining Nes-Cre mediated Gmnn excision with the 
SmoA1 model of murine medulloblastoma. This mouse 
model of the human SHH medulloblastoma subtype 
expresses an activated form of Smoothened (SmoA1) 
specifically in GNPs [53], under control of the NeuroD2 
promoter (ND2) [54]. These mice exhibit excessive 
GNP proliferation and 48% of the animals develop 
medulloblastoma, with a median of 6 months of age [53].
 We initially compared Gmnn expression levels in 
GNPs prepared from SmoA1 versus wildtype cerebellum 
at P6: Gmnn levels were elevated in SmoA1 transgenic 
animals (both males and females), compared to wild-type 
animals (Figure 2B). Cohorts of P14 male and female 
Figure 1: Geminin is highly expressed in human and mouse medulloblastoma. (A) Elevated Gmnn expression was detected 
in four human medulloblastoma microarray datasets relative to normal cerebellum. (B-C) Top genes (B) and gene ontology (GO) terms 
(C) whose expression most strongly correlated with Gmnn expression were defined in 103 medulloblastoma samples (Northcott core 
transcript; GSE21140) using R2 (see Methods). (D) Gmnn and Ki67 immunostaining of cerebellar sections from an adult SmoA1 mouse 
with medulloblastoma. Boxed insets (right panels) at the tumor boundary (marked with arrowheads) show relative expression levels in 
normal cerebellum (left) versus tumor (right) for Gmnn and Ki67. Scale bars= 500µm (left) and 100µm (right).
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adults were then generated, all of which carried one 
copy of the Nes-Cre and SmoA1 transgenes and were 
either heterozygous or homozygous for the floxed Gmnn 
allele. Western blotting for Gmnn levels in cerebellar 
tissues from these SmoA1; Nes-Cre; Gmnnfl/fl animals 
revealed complete loss of Gmnn protein by comparison 
to their SmoA1; Nes-Cre; Gmnn+/fl littermates, which 
retained Gmnn expression (Figure 2C). We tracked 
cohorts of animals with these genotypes (n=14 animals 
in each group; including males and females) for one year. 
Adult SmoA1 mice that developed clinical symptoms of 
medulloblastoma (enlarged posterior fossa, tilted head, 
hunched posture, ataxia) were euthanized and histological 
sectioning of the brain was performed to confirm the 
presence of a tumor.
As seen previously for the SmoA1 medulloblastoma 
model [53], ~50% of both males and females with a copy 
of wild-type Gmnn developed tumors and did not survive 
beyond 6 months. By contrast, animals homozygous for 
the Gmnn floxed allele (SmoA1;Nes-Cre; Gmnnfl/fl) had 
a substantial survival advantage, relative to SmoA1;Nes-
Cre;Gmnn+/fl animals that retained wild type Gmnn 
function (Figure 2D). This effect was significant for both 
males and females (Supplementary Figure 2), but was 
more pronounced for males, with ~80% of the SmoA1; 
Nes-Cre; Gmnnfl/fl animals surviving through the end of 
the study. Upon histological sectioning, all symptomatic 
animals exhibited large tumors that were usually detected 
bilaterally in parasagital sections through the brain, 
while very few animals that were asymptomatic through 
the end of the study exhibited a visible tumor mass 
(Supplementary Figure 3). We examined tumor size and 
histology by hematoxylin-eosin staining and also analyzed 
a subset of the tumors by immunofluorescence for Ki-67 
Figure 2: Geminin loss of function enhances survival in the SmoA1 medulloblastoma model. (A) In the cerebellum of P5 
mice, Gmnn is expressed in the EGL in a pattern like Ki67, which marks proliferative cells. Scale bar=100µm. (B) Gmnn mRNA levels 
were defined by qRTPCR analysis in P6 GNP preparations from individual wild-type (n=4) versus SmoA1 transgenic males (n=2) and 
females (n=5), and is expressed as a normalized fold difference. **p<0.01 was defined by two-tailed student’s t-test. ns=not significant. (C) 
Gmnn protein levels in SmoA1; Nes-Cre; Gmnn+/fl versus Gmnnfl/fl cerebella at P14, defined by Gmnn immunoblotting with γTubulin as a 
loading control. (D) Kaplan-Meier survival plot for cohorts of mice hemizygous for both the Nestin-Cre and SmoA1 transgenes and either 
heterozygous or homozygous for the floxed Gem allele. Animals were euthanized when they exhibited neurologic impairment or morbidity 
or at the end of the study and presence or absence of tumors was confirmed.
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Figure 3: Geminin loss reduces numbers of persisting preneoplastic GNPs in SmoA1 transgenic mice. (A) Thickness 
of the EGL layer in P14 cerebella hemizygous for the Nes-Cre and SmoA1 transgenes and heterozygous or homozygous for the Gmnn 
floxed allele. Control comparison to animals not carrying the SmoA1 transgene is also shown. Matched cerebellar sections with insets 
corresponding to labelled regions at right. (B) Quantitation for A, n=3 animals for each genotype, with matched 5µm sections analyzed for 
each animal (see Methods) and the percentage of sections with >2-3 persisting EGL cell layers scored as thickened for 3 animals for each of 
the three genotypes. (C) At P28, cerebella of the same genotypes as in A are shown, with pGNPs persisting at the cerebellar surface staining 
darkly in the H&E stained brain sections (marked by arrowheads). (D) Averaged counts/section were from 4 matched serial sections per 
P28 brain. Number of animals per genotype analyzed: n=11 (SmoA1; Nes-Cre; Gmnn+/fl), n=10 (SmoA1; Nes-Cre; Gmnnfl/fl), n=6 (Nes-
Cre; Gmnn+/fl). *<0.05, **<0.01 were defined by two-tailed student’s t-test.
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and NeuN, marking proliferating and differentiated cells 
in the tumor, respectively (Supplementary Figure 3). All 
of these characteristics appeared similar in tumors with 
either the SmoA1;Nes-Cre;Gmnn+/fl or SmoA1;Gmnnfl/
fl genotypes. As tumors were processed for histology as 
animals in the cohort became symptomatic, these data did 
not reveal whether the rate of tumor growth was altered 
by Gmnn deficiency. However, the size, histology, and 
proliferative index of tumors that were analyzed did 
not appear to differ by genotype, despite the survival 
advantage conferred by Gmnn deficiency. 
Geminin deficiency reduces the persistence of 
preneoplastic cells in SmoA1 mice
The work above demonstrated that Gmnn deficiency 
could enhance survival in a model of medulloblastoma 
driven by constitutively active Shh signaling. Since 
both Gmnn-expressing and Gmnn-deficient cells could 
contribute to tumors, we examined whether the survival 
advantage conferred by Gmnn deficiency might relate 
to an altered propensity of preneoplastic cells to form 
tumors. In mouse models with constitutive Shh pathway 
activation, medulloblastoma tumorigenesis shows several 
stages of progression, with clusters of preneoplastic 
GNPs (pGNPs) that actively express Shh target genes 
such as cyclin D1 remaining on the surface of the mature 
cerebellum. These cells can be considered a preneoplastic 
intermediate, some of which develop into larger lesions 
and then tumors [55-58]. In SmoA1 transgenic mice, 
the tumorigenic effect of SmoA1 is balanced by tumor 
suppressive mechanisms, such that while all mice develop 
pGNPs, not all develop tumors. Control of proliferation, 
differentiation, and apoptosis all limit the growth of 
pGNPs [58, 59]. During the latent period that precedes 
tumor detection in multiple medulloblastoma mouse 
models, pGNPs acquire additional oncogenic changes 
that mediate progression from the precursor state to a fully 
tumorigenic state. Therefore, we assessed whether Gmnn 
deficiency could alter pGNP proliferation, differentiation, 
or survival during the postnatal period. 
To assess whether Gmnn deficiency modified the 
growth or survival of preneoplastic GNPs, we initially 
analyzed early hyperplastic lesions in the SmoA1 
medulloblastoma model. During normal development, 
the P14-P16 EGL is comprised of 2-3 GNP cell layers, 
as most GNPs have completed their migration into the 
IGL (for example, in Nes-Cre; Gmnn+/fl animals lacking 
the SmoA1 transgene, Figure 3A). At this time, mice with 
a single copy of the SmoA1 transgene have thickened 
EGL regions, expanded as nodular formations within the 
cerebellar lobules. At P14, heterozygous mice that retained 
Gmnn activity (SmoA1; Nes-Cre; Gmnn+/fl) displayed 
thicker EGL regions than animals homozygous for the 
Gmnn floxed allele (SmoA1; Nes-Cre; Gmnnfl/fl) (Figure 
3A-3B). This phenotype was also seen in cerebellar 
sections from SmoA1 transgenic animals at P16, with 
increased EGL thickness apparent in SmoA1; Nes-Cre; 
Gmnn+/fl animals by comparison with SmoA1; Nes-Cre; 
Gmnnfl/fl animals (Supplementary Figure 4). These data 
suggest that, relative to heterozygous animals expressing 
Gmnn, loss of Gmnn results in fewer SmoA1 expressing 
GNPs with preneoplastic potential remaining at the 
cerebellar surface. 
By four postnatal weeks (P28), the EGL has largely 
disappeared (Figure 3C, Nes-Cre; Gmnn+/fl animal lacking 
the SmoA1 transgene). However, in mice carrying the 
SmoA1 transgene at this stage, foci of ectopic proliferative 
preneoplastic GNPs (pGNPs) are still present on the 
external cerebellar surface. These may be classified as 
focal hyperplasias (<30 pGNPs) or diffuse hyperplasias 
(>5000 cells). As many of these cells do not develop into 
tumors, medulloblastoma incidence is influenced both by 
the frequency with which GNPs become preneoplastic in 
early postnatal life and with the survival, persistence, and 
continued proliferation of these cells to form tumors. We 
therefore generated sex-matched littermates that carried 
one copy of the SmoA1 and Nestin-Cre transgenes and 
were also either heterozygous or homozygous for the 
floxed Gmnn allele, comparing cerebellar sections from 
these animals at P28. Animals homozygous for Gmnn 
loss (SmoA1; Nes-Cre; Gmnnfl/fl) had six-fold fewer 
preneoplastic cells than SmoA1; Nes-Cre; Gmnn+/fl 
animals retaining wild-type Gmnn (Figure 3C-3D, pGNP 
cell counts for individual animals are in Supplementary 
Figure 5). In addition, we found that some P28 SmoA1; 
Nes-Cre; Gmnn+/fl animals had severe cerebellar dysplasia, 
while we never observed this phenotype in SmoA1; Nes-
Cre; Gmnnfl/fl animals (Supplementary Figure 6). Together, 
these data suggest that Gmnn deficiency alters the 
proliferation, differentiation, and/or survival of pGNPs. 
Therefore, we next assessed whether alteration of these 
properties could account for the significant decrease 
in pGNPs under conditions of Gmnn deficiency in the 
SmoA1 transgenic model.
Geminin deficiency reduces the persistence of 
preneoplastic granule neuron precursor cells in 
the SmoA1 model by activation of a DNA damage 
response and apoptosis 
 In our work above, we demonstrated that Nes-
Cre-driven Gmnn deficiency enhanced survival in the 
SmoA1 medulloblastoma mouse model. Likewise, at 
P28, SmoA1; Nes-Cre; Gmnnfl/fl cerebella exhibited 
significantly fewer pGNPs than were seen in cerebella of 
SmoA1; Nes-Cre; Gmnn+/fl animals. These data suggested 
that Gmnn deficiency compromised the persistence of 
pGNPs, which could account for decreased rates of 
Genes & Cancer731www.impactjournals.com/Genes&Cancer
tumor formation in these animals. This reduction in 
numbers of persisting pGNPs could result from enhanced 
differentiation, diminished proliferation, or altered 
survival of pGNPs.
To address which of these mechanisms could 
contribute to the reduced numbers of pGNPs observed 
in the SmoA1; Nes-Cre; Gmnnfl/fl animals, we 
immunostained cerebella from P14 SmoA1; Nes-Cre; 
Gmnn+/fl and SmoA1; Nes-Cre; Gmnnfl/fl littermates 
with antibodies against γH2AX (induction of DNA 
damage response), cleaved (active) Caspase-3 (apoptotic 
marker), phosphorylated histone H3 (pH3; mitotic cell 
marker), p27kip1 (cell cycle exit accompanying GNP 
differentiation), and CyclinD1 (proliferative cell marker). 
We observed a significant increase in the fraction of 
pGNPs expressing both γH2AX (Figure 4A, 4C) and 
active Caspase-3 (Figure 4B, 4D) in SmoA1; Nes-Cre; 
Gmnnfl/fl cerebella, by comparison with littermates that 
retained Gmnn activity (SmoA1; Nes-Cre; Gmnn+/fl). 
This result suggests that Gmnn loss results in increased 
accumulation of DNA damage and apoptotic cell death of 
pGNPs. An adjacent matched section for each genotype 
was also stained with hematoxylin and eosin, confirming 
the differences in overall thickness of the EGL in the 
sections examined (Figure 4E). By contrast, there did 
not appear to be significant differences in the fraction of 
pGNPs that were immunopositive for Cyclin D1, p27kip1, 
or pH3 in the SmoA1; Nes-Cre; Gmnn+/fl versus SmoA1; 
Nes-Cre; Gmnnfl/fl backgrounds (Supplementary Figure 
7), suggesting that Gmnn deficient pGNPs could still 
proliferate and undergo cell cycle exit and differentiation. 
These results suggest that Gmnn loss sensitizes pGNPs to 
accumulation of DNA damage and apoptosis, which could 
account for the reduced numbers of persisting pGNPs 
and the enhanced survival observed in SmoA1; Nes-Cre; 
Gmnnfl/fl animals.
Geminin knockdown induces cell cycle arrest of 
human medulloblastoma cells 
SmoA1 pGNPs and tumor cells from the mouse 
model are not amenable to long-term culture ex vivo (data 
not shown). Therefore, to further assess whether Gmnn 
deficiency could affect medulloblastoma cell proliferation, 
growth, and/or survival, we also manipulated Gmnn levels 
in Daoy cells, a widely used human medulloblastoma 
cell line that mimics some characteristics of the Shh 
medulloblastoma subtype [60-62]. We performed a dose 
response curve to identify the lowest concentration of 
small interfering RNAs (siRNAs) that significantly 
reduced Gmnn levels in Daoy cells (Supplementary Figure 
8). We validated two independent siRNAs directed against 
human Gmnn, each of which induced 85-90% reduction 
in Gmnn protein levels, with siGmnn#6 consistently 
reducing Gmnn levels even more strongly than siGmnn#2 
(Figure 5A-5B). Acute Gmnn knockdown with both 
siRNAs significantly impaired Daoy cell growth in vitro, 
resulting in a plateau and subsequent decline in cell 
numbers (Figure 5C). 
We conducted cell cycle analysis in Daoy cells 
72 hours after Gmnn or control (GAPDH) siRNA 
knockdown, without prior synchronization of the cell 
population. Gmnn knockdown resulted in a significant 
accumulation of cells with 4N DNA content, e.g. in the 
G2/M phases of the cell cycle (Figure 5D-5E). To better 
quantify the increased numbers of 4N (G2/M phase) 
cells following Gmnn knockdown, we synchronized 
the cell population in G1/S by hydroxyurea treatment 
(treatment conditions defined in Supplementary Figure 
9). Gmnn knockdown likewise induced accumulation of 
these synchronized Daoy cells in G2/M, with pronounced 
effects seen in synchronized cell populations 48 hrs. after 
hydroxyurea release, corresponding to 72 hrs. of Gmnn 
knockdown (Figure 5F-5G). We next assessed whether 
Gmnn knockdown caused Daoy cells to arrest in the G2 
or M phase of cell cycle, by combining FACS for a mitotic 
marker (phosphorylated histone H3; pH3) with propidium 
iodide analysis for cellular DNA content. No reproducible 
differences in numbers of M-phase cells were detected 
in the Gmnn siRNA condition, by comparison with the 
GAPDH siRNA control (Figure 6). These results suggest 
that Gmnn knockdown causes significant accumulation of 
cells in the G2 phase rather than M phase of the cell cycle.
Geminin depletion induces activation of G2 
checkpoint and DNA damage response pathways 
and apoptosis in human medulloblastoma cells
Gmnn deficient Daoy cells accumulated in the 
G2 phase of the cell cycle. This could potentially occur 
subsequent to DNA damage incurred during S phase, 
such as DNA re-replication by unimpeded Cdt1 activity, 
and the resulting replication stress would be expected to 
activate DNA damage checkpoint pathways. Therefore, to 
assess checkpoint pathway activation, we compared levels 
of phosphorylated, activated Chk1 and Chk2 checkpoint 
kinases in control versus Gmnn knockdown Daoy cells. 
Both Gmnn siRNAs strongly induced activation of Chk1, 
while the more effective knockdown construct (siGmnn#6) 
also induced strong activation of Chk2 (Figure 7A-7D). 
As recruitment of γH2AX to chromatin is an early 
indicator of activation of DNA damage repair processes, 
we performed immunostaining for γH2AX to test whether 
Gmnn deficiency triggered a DNA damage response. 
Etoposide treated Daoy cells were used as a positive 
control for DNA damage and these cells stained positive 
for γH2AX (Figure 7E). While γH2AX immunopositive 
cells were not seen in control siRNA transfected cells, 
Gmnn depletion with both siRNAs resulted in formation 
of γH2AX -positive foci in >75-80% of cells (Figure 7E, 
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Figure 4: Geminin loss increases pGNPs expressing markers of the DNA damage response and apoptosis. 
Immunohistochemistry for γH2AX and cleaved (active) Caspase3 on P14 cerebellar sections from animals hemizygous for the Nes-Cre and 
SmoA1 transgenes and either heterozygous or homozygous for the Gmnn floxed allele. Matched representative sections are shown for each 
genotype in (A-B), with matched hematoxylin-eosin stained sections in E. (C-D) Immunopositive pGNPs were quantified and represented 
as average counts/section with *<0.05 defined by two-tailed student’s t-test.
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7G). As failure to repair DNA damage may trigger cell 
death by apoptosis, we also assessed the status of cleaved 
Caspase-3, a marker for apoptosis, in control and Gmnn 
knockdown cells. By comparison with control cells, 
knockdown of Gmnn significantly increased levels of 
cleaved Caspase-3, as assessed by both immunostaining 
and Western blotting analyses (Figure 7F, 7H-7I). 
Interference with Geminin activity acts 
synergistically with the topoisomerase inhibitor 
etoposide
Standard treatment for medulloblastoma includes 
maximal safe tumor resection, followed by craniospinal 
irradiation and multi-agent chemotherapy [39]. The 
topoisomerase inhibitor etoposide (VP-16) has been 
Figure 5: Geminin knockdown causes DNA re-replication and G2/M cell cycle arrest in human medulloblastoma 
cells. (A). Gmnn siRNA knockdown in Daoy cells was performed using 25 nM of Gmnn siRNAs #2 or #6 (see Methods) and levels 
of knockdown were assessed after 72hrs by Western blotting (A) and by qRTPCR (B), revealing ~90% knockdown achieved with each 
siRNA. (C) Growth curve: 6X105 cells were seeded and siRNA transfection was performed 24 hrs later (time 0). Numbers of cells were 
counted 24, 48, and 72 hr. post-transfection. (D-E) 72 hrs. after Gmnn siRNA knockdown, cells were stained with propidium iodide and 
1X106 cells for each condition were analyzed for DNA content using FACS. Representative FACS plots are shown in D. In E, the fraction 
of cells with 4N DNA content following Gmnn siRNA knockdown is represented as a fold ratio relative to the GAPDH siRNA control. 
An average value obtained from four independent biological replicates is shown. (F-G) Daoy cells were synchronized with hydroxyurea 
as described (Methods) and effectiveness of synchronization (arrest of cells in G1/S) is shown in Figure S9. Percentages of cells in G2/M 
were determined by FACS analysis and quantified as described in D-E, for 3 independent biological replicates. p-values: *<0.05, **<0.01, 
***<0.001 were defined by two-tailed student’s t-test.
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used as a component of combinatorial chemotherapy for 
newly diagnosed and recurrent medulloblastoma [63-65]. 
Interestingly, in addition to interacting with Cdt1, Gmnn 
can interact with Topoisomerase IIα (Topo IIα), a target 
for etoposide, which resolves chromosomal catenanes 
formed during DNA replication [12, 66]. Gmnn was 
reported to both promote recruitment of Topo IIα to 
chromatin during replication and to stimulate its release 
from chromosomes. Accordingly, in some cell contexts, 
Gmnn over-expression triggers premature Topo IIα release 
from chromosomes, increasing cellular resistance to the 
Topo IIα poisons etoposide and doxorubicin, which act 
by trapping the chromosomally bound transient reaction 
intermediate [12, 66]. 
Since Gmnn can interact with Topo IIα, and 
Topo IIα inhibitors like etoposide are used to treat 
medulloblastoma, we additionally investigated whether 
Gmnn inhibition could potentiate etoposide efficacy. 
We began by performing a dose-response for etoposide 
treatment of Daoy cells, to identify a dose that caused a 
modest accumulation of cells in the G2 phase (Figure 8A). 
We used this dose (100nM) of etoposide in combination 
with control or Gmnn knockdown and found that Gmnn 
inhibition using either siRNA acts additively with 
etoposide to increase the G2 accumulation of Daoy 
cells (Figure 8B-8C). Taken together, these data suggest 
that inhibition of Gmnn can induce cell cycle arrest, 
DNA damage checkpoint activation, and apoptosis of 
medulloblastoma cells, and could potentially sensitize 
tumor cells to combination chemotherapies involving 
etoposide.
Nestin-Cre-mediated Geminin excision in the 
nervous system does not alter motor, cognitive, or 
other behavioral functions
Since medulloblastoma develops during childhood, 
selective therapies should target cancer cells without 
affecting normal neurodevelopment or neurological 
function. Therefore, to determine whether Gmnn inhibition 
represented a plausible approach for selective targeting of 
cancer cells in medulloblastoma, we thoroughly examined 
effects of Gmnn loss on neurological function in the 
Nes-Cre conditional knockout model. Using a range of 
behavioral assays, we assessed age-matched male and 
female cohorts of adults carrying one copy of the Nes-
Cre transgene that were either wild-type for Gmnn or 
homozygous for the floxed Gmnn allele. We first assessed 
possible impairment of learning and memory and simple 
motor and sensorimotor functions, which might confound 
performance in cognitive tests. This involved quantifying 
performance during a one hour locomotor activity and 
exploratory behavior test, a battery of sensorimotor 
measures, and the Morris water navigation task. We also 
conducted a series of additional tests at a slightly older age 
to evaluate other behavioral parameters. These included 
the elevated plus maze, acoustic startle/pre-pulse inhibition 
of startle, hole board exploration/olfactory preference, 
and social approach, in that order. None of these tests 
revealed a distinct behavioral phenotype resulting from 
Nes-Cre-mediated conditional loss of Gmnn function 
(Supplementary Figure 10 and Supplemental Results 
and Methods). Our behavioral testing efforts do not 
qualify as a definitive evaluation of all possible untoward 
effects of conditional loss of Gmnn function. However, 
our data suggest that therapeutic interventions involving 
targeting of Gmnn activity in the developing nervous 
system are unlikely to have major deleterious effects on 
neurodevelopment or neurological function. 
DISCUSSION
Geminin deficiency suppresses medulloblastoma 
tumorigenesis
The Shh-driven subtype accounts for about 30% 
of all medulloblastomas [44, 67], with GNPs serving as 
Figure 6: Geminin knockdown results in cell cycle arrest in G2 rather than M phase. Representative FACS plots of cells 
analyzed for DNA content (PI: x-axis) and by immunocytochemistry for pH3 (y-axis). Similar percentages of highly pH3 immunopositive 
cells (M-phase cells) were seen in all three knockdown conditions. 
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the cell of origin [68, 69]. During cerebellar development 
in the mouse, GNP proliferation in the EGL is maximal 
at about one week after birth, while by three weeks the 
GNPs have differentiated and migrated into the IGL. 
In the SmoA1 model at P14-P16, the EGL remains 
thickened with clusters of GNPs with preneoplastic 
potential remaining at the cerebellar surface. However, 
Gmnn deficiency partially suppressed these effects. These 
effects were also seen at four postnatal weeks, when Gmnn 
loss reduced the persistence of pGNPs at the cerebellar 
surface by six-fold in the SmoA1 model. These findings 
correspond with altered frequencies of tumorigenesis in 
cohorts of SmoA1 transgenic animals with versus without 
Gmnn loss, with Gmnn loss conferring a significant 
survival advantage. These data suggest that Gmnn 
deficiency may modify pGNP tumorigenic potential from 
an early developmental timepoint, diminishing pGNP 
persistence at the cerebellar surface and reducing the rate 
at which medulloblastoma tumors form under conditions 
of constitutively active Shh signaling.
Figure 7: Geminin depletion induces G2 checkpoint activation, DNA damage response, and apoptosis in human 
medulloblastoma cells. (A-B) siRNA knockdown was performed on unsynchronized Daoy cells as above. Representative westerns 
for phosphorylated-Chk1 and Chk2 are shown relative to total Chk1/2 and to the γTubulin loading control. (C-D) Quantitation of changes 
in phosphorylated Chk1/2 was performed by quantification of band intensity and is represented as the average of two experiments. (E-F) 
Immunocytochemistry for γH2AX and activated Caspase-3 was performed on siRNA transfected cells. Representative images are shown, 
with etoposide used as a positive control to induce DNA damage in E. Scale bars=50µm. (G-H) Quantification of data from E-F was 
obtained by scoring >250 cells per sample type per experiment for three independent experiments. (I) Western blotting for cleaved caspase 
was assessed in the siRNA transfected cells. p-values: *<0.05, **<0.01, ***<0.001 were defined by two-tailed student’s t-test. ns=not 
significant.
Genes & Cancer736www.impactjournals.com/Genes&Cancer
Figure 8: Interference with Geminin activity acts synergistically with the topoisomerase inhibitor etoposide. (A) 
Etoposide dose response curve was generated by treating Daoy cells with increasing concentrations of etoposide and evaluation of DNA 
content by propidium iodide staining and FACS analysis. 100 nM was selected as a dose for assessing interactions with Gmnn knockdown 
in subsequent experiments. (B-C) PI FACS analysis as described previously was performed on Gmnn siRNA knockdown cells with addition 
of DMSO vehicle or 100 nM etoposide. (B) Quantification of three independent experiments. Ratio of G2/M (4N) cells in etoposide, 
compared with the DMSO control, is shown for each knockdown condition. (C) One representative experiment (of three independent 
experiments) is shown. p-values: *<0.05, **<0.01 were defined by two-tailed student’s t-test. 
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 As modulating pathways that affect pGNP 
proliferation, differentiation, or survival can all affect the 
frequency of tumor formation [49, 70], we assessed which 
processes were affected by Gmnn deficiency in the SmoA1 
model. We found no significant difference in the fraction 
of pGNPs expressing cyclin D1, the mitotic marker pH3, 
or p27Kip1 in cerebella of SmoA1 retaining versus with loss 
of Gmnn expression. These data suggest that loss of Gmnn 
did not grossly alter the ability of pGNPs to proliferate, 
exit the cell cycle, or differentiate. By contrast, Gmnn 
loss in the SmoA1 model significantly increased relative 
numbers of pGNPs immunopositive for γH2AX , which 
marks cells with DNA damage, and cleaved Caspase-3, 
which labels cells undergoing apoptosis. These data 
suggest that Gmnn deficiency can trigger a DNA damage 
response in pGNPs in the SmoA1 model from early stages, 
elevating rates of pGNP apoptosis. This may account for 
the reduced numbers of pGNPs persisting at the cerebellar 
surface at later postnatal stages and for the survival 
advantage later observed in these animals.
Geminin is required to maintain the fidelity of 
DNA replication in medulloblastoma
The pre-RC protein Cdt1 is essential for loading 
DNA helicases onto origins of DNA replication. Cdt1 
inactivation prevents genome re-replication within a cell 
cycle and occurs through multiple mechanisms [4-9]. 
During S-phase, cyclinA:CDK2 complexes phosphorylate 
Cdt1, targeting it for SCFSkp2–dependent ubiquitination, 
while CDRDdb1 also ubiquitinates Cdt1, both of which 
promote Cdt1 proteolysis. Gmnn’s ability to specifically 
bind to Cdt1 during S/G2 phases of the cell cycle 
constitutes a third system for controlling Cdt1 activity, 
both preventing Cdt1 from reinitiating DNA replication 
and also protecting Cdt1 from proteolytic degradation [1, 
2, 4, 7, 9].
 Since Gmnn inhibits Cdt1, Gmnn depletion 
can result in genome re-replication within a cell cycle, 
through increased Cdt1 activity. However, prior work 
had suggested that cells derived from normal tissues 
and cancer cells may exhibit differential dependence 
upon Gmnn to prevent DNA re-replication [10]. In Zhu 
et al., siRNA knockdown of Gmnn caused re-replication 
and triggered apoptosis in a wide variety of cancer cell 
lines, while inducing similar effects in non-cancer cell 
lines required combined suppression of Gmnn and 
Cyclin A [10]. These data suggest that Gmnn may be 
the primary regulator of Cdt1 inhibition in cancer cells, 
while additional safeguards are sufficient to constrain 
DNA re-replication to maintain genome fidelity in many 
non-cancer cell contexts. Preferential sensitivity of 
some cancer cells to Gmnn depletion may involve their 
overexpression of pre-RC proteins including Cdt1 and 
Cdc6, which stimulate pre-RC complex re-assembly and 
re-firing of origins of replication within the same cell cycle 
[11]. Gmnn expression is elevated in many tumor cells, 
and may constrain this additional pre-RC complex activity, 
such that altering this balance by Gmnn depletion would 
preferentially trigger DNA damage due to re-replication 
and checkpoint arrest in cancer cells. Interestingly, here 
we found that Gmnn levels in human medulloblastomas 
did not correlate with tumor subtype, histology, or other 
criteria, but did correlate with elevation of cell cycle 
related genes, including pre-RC proteins (MCM6, ORC1, 
and ORC6). This would be compatible with a need for 
elevated Gmnn to balance increased pre-RC expression, 
to maintain genome integrity and facilitate tumor growth.
Gmnn inhibition elicits distinct, cell type-specific 
responses. In some cells, Gmnn inhibition results in 
extensive genome re-replication, with G2 checkpoint 
arrest triggered by production of aneuploid cells with >4N 
DNA content. However, other cell types (for example, 
immortalized human mammary epithelial cells) undergo 
mitotic rather than G2 arrest upon Gmnn silencing [66, 
71]. In these cells, Gmnn loss does not cause S phase 
progression defects or genome over-replication, but rather 
causes mitotic arrest, inability to exit mitosis, and the 
formation of unresolved chromosomal bridges. We found 
that inhibition of Gmnn in human Daoy medulloblastoma 
tumor cells caused accumulation of cells in G2 without 
significant changes in numbers of M-phase cells. 
However, unlike the cancer cell lines characterized by Zhu 
et al., in which 28-44% of cells exhibited extensive DNA 
re-replication [10], Gmnn depletion in Daoy cells resulted 
in a much more modest fraction of >4N cells. However, 
70-80% of these cells accumulated γH2AX-positive 
DNA damage foci and underwent spontaneous apoptosis, 
measured by cleaved Caspase-3 immunopositivity. 
Blow and colleagues have suggested that levels 
of re-replication resulting from Gmnn depletion may be 
influenced by the length of G2 arrest, with prolonged G2 
checkpoint arrest enabling Cdt1 accumulation, which 
promotes additional genome re-replication and greater 
DNA damage [72]. This may constitute a protective 
response, making re-replication into an all-or-nothing 
phenomenon to prevent accumulation of cells with low 
levels of re-replication [72]. Modest induction of re-
replication subsequent to either Gmnn deficiency or Cdt1 
overexpression is sufficient to induce G2 checkpoint 
activation [72, 73]. Inappropriate re-licensing can also 
result in other forms of DNA damage, including head-
to-tail replication fork collision and the tendency of 
re-replicating forks to collapse [74, 75]. Therefore, 
even minor induction of re-replication or other types of 
replication stress (for example, those related to altered 
Topo IIα decatenation activity) could also damage the 
genome in S phase in a manner that may not be apparent 
as a significant fraction of G2/M cells with >4N DNA 
content. The ability of minor amounts of replication 
stress to trigger a DNA damage response and subsequent 
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apoptosis could account for the results seen here in vivo. 
In the SmoA1 model, Gmnn deficiency strongly induced 
γH2AX and cleaved Caspase-3 immunopositivity in 
pGNPs. By P28, these Gmnn deficient animals had 
six-fold fewer pGNPs at the cerebellar surface, likely 
contributing to the enhanced survival of the Gmnn-
deficient cohort. However, the SmoA1 tumors that did 
form in Gmnn-deficient animals had similar fractions 
of proliferative cells as those without Gmnn deficiency, 
while the fraction of pGNPs expressing proliferative cell 
markers was not grossly altered by Gmnn deficiency. 
These findings suggest that Gmnn-deficient preneoplastic 
and cancer cells may be sensitized, potentially by 
incurring DNA damage, to undergo apoptosis even under 
conditions where they do not exhibit cell cycle arrest or 
grossly altered proliferative capacity. 
Both in mouse in vivo and human in vitro models 
of medulloblastoma, Gmnn deficiency triggered a 
DNA damage response and apoptosis. In human 
medulloblastoma cells, the DNA damage response was 
accompanied by activation of both ATR/Chk1, which is 
activated in response to DNA damage other than double 
strand breaks, including replication stress, and ATM/Chk2, 
which is activated predominantly in response to double 
strand breaks [76, 77]. Interestingly, Gmnn knockdown 
using the two siRNAs yielded slightly different results, 
with siGmnn-2 only activating pChk1 while siGmnn-6 
activated both pChk1 and pChk2. The siGmnn-6 construct 
yields higher knockdown of Gmnn compared to siGmnn-2, 
suggesting that the extent of Gmnn loss may affect the 
nature and extent of DNA damage that occurs upon Gmnn 
knockdown in medulloblastoma cells, with the siGmnn-2 
construct predominantly triggering replication stress 
leading to ATR/Chk1 activation, while more effective 
knockdown with siGmnn-6 resulted both in higher levels 
of replicative stress and induction of double strand DNA 
breaks, activating both pChk1 and pChk2. 
In some cancer cell contexts, effects of Gmnn 
inhibition have been shown to be independent of the 
mutational status of the tumor suppressor TP53, with 
Gmnn loss inducing accumulation of excess genomic 
DNA, G2/M checkpoint activation, and apoptosis in both 
TP53+ and TP53- cells [10, 78, 79]. We focused our in 
vitro studies here on the Daoy human medulloblastoma 
cell line. Daoy cells are the oldest established 
medulloblastoma cell line: they were first isolated in 
1985 from a 4-year old boy [60] and have been utilized 
in more studies than any other medulloblastoma cell line 
[61], with molecular subtyping indicating that they mimic 
the SHH pathway activated subtype of medulloblastoma 
[62]. The Daoy cell line harbors a single point mutation of 
the tumor suppressor TP53, resulting in a substitution of 
phenylalanine for a cysteine at amino acid 242 and loss of 
functional p53 [80, 81]. By contrast, the SmoA1 mouse 
model used here has intact TP53 activity. TP53 mutations 
are only found in a fraction of human medulloblastomas 
of the Wnt (16%) and Shh (21%) subtypes, although 
they correlate with poor survival and treatment failures 
in Shh-driven medulloblastoma [38, 82, 83]. However, in 
both of our experimental models, loss of Gmnn resulted 
in a similar induction of the DNA damage response 
and apoptosis. This suggests that, as in other cancer 
cell contexts, Gmnn inhibition can elicit some effects 
regardless of TP53 status, such that Gmnn-directed 
therapeutics could potentially have similar efficacy in both 
TP53+ and TP53- forms of medulloblastoma. 
Geminin deficiency sensitizes medulloblastoma 
cells to etoposide treatment
Another mechanism by which Gmnn levels could 
influence genome integrity is through interactions with 
Topo IIα, which removes catenated intertwines between 
sister chromatids to separate replicated chromosomes. 
Gmnn-Topo IIα interaction may facilitate Topo IIα 
activity during termination of DNA replication [66]. In 
human mammary epithelial (HME) cells, physiologically 
normal Gmnn levels are needed to both facilitate Topo 
IIα recruitment to chromosomes, by promoting Topo IIα 
phosphorylation, and for recruitment of deSUMOylating 
enzymes to Topo IIα, to promote its release from 
chromatin. In that work, Gmnn over-expression promoted 
premature Topo IIα release from chromatin and increased 
the resistance of HME and breast cancer cells to Topo 
IIα inhibitors such as etoposide, which trap the transient 
Topo IIα reaction intermediate on chromatin to prevent 
DNA religation and promote cell death. These findings 
suggested that the high levels of Gmnn expression we 
observed in medulloblastoma could contribute to etoposide 
resistance, while inhibiting Gem might chemosensitize 
cells in multi-agent chemotherapy treatments involving 
etoposide. We found that Gmnn inhibition indeed 
enhanced the responsiveness of medulloblastoma cells to 
etoposide treatment, significantly increasing the fraction 
of cells that underwent G2 checkpoint arrest. Therefore, 
given the utilization of etoposidase and other Topo IIα 
inhibitors in current medulloblastoma chemotherapies, 
inhibition of Gmnn in this context might have the potential 
to enhance efficacy and/or re-sensitize resistant cells. 
We performed these experiments in the Daoy cell line, 
because it is amenable to in vitro culture, while we could 
not culture tumor cells from the SmoA1 mouse model 
ex vivo. However, the Daoy model has limitations as a 
model of medulloblastoma: it is hypertetraploid, with 
a modal chromosome number of 93-99, and carries a 
TP53 mutation, while most human medulloblastomas 
do not exhibit these features [60, 61, 80, 81]. Therefore, 
in future studies, it would be of interest to test whether 
Gmnn loss or inhibition could also enhance the efficacy 
of etoposide treatment in the context of in vivo models of 
medulloblastoma.
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Since medulloblastoma is a childhood cancer that 
occurs during development and maturation of the nervous 
system, we also assessed whether Gmnn inhibition could 
be used to selectively target cancer cells without affecting 
nervous system development or neurological function. 
Prior work describing neurodevelopmental phenotypes 
of Nes-Cre-mediated Gmnn loss has yielded conflicting 
results. Schultz et al. described these animals as having 
normal neural stem cell function and normal neurogenesis 
[52], while Spella et al. suggested that Nes-Cre-driven 
Gmnn loss led to expansion of neural progenitors during 
ex vivo cortical progenitor culture [84]. One experimental 
variable that may underlie these conflicting findings is 
use of different Nes-Cre transgenic lines with distinct 
sites of integration, which may influence transgene 
expression. Our work here used (Nes-cre)1Kln, which 
was previously documented to result in significantly 
diminished Gmnn protein in CNS tissues by E14.5 [52]. 
Using this Nes-Cre driver, Gmnn loss did not result in 
detectable alterations of neurological function, which was 
assessed by conducting an extensive panel of behavioral 
and motor assays. Therefore, these data suggest that Gmnn 
requirements for neural development are restricted to early 
embryogenesis and support the potential utility of Gmnn 
directed therapeutics in selective targeting of cancer cells 
in medulloblastoma. 
Efforts are underway to define small molecules that 
induce cancer-selective induction of re-replication, cell 
cycle arrest, and spontaneous apoptosis, by inhibiting 
the activity of Gmnn or of other molecular controls that 
prevent excessive DNA replication [12, 78]. Our work 
here demonstrates that, while Gmnn appears largely 
dispensable for normal neurodevelopment and normal 
neurological function after early embryogenesis, Gmnn 
inhibition can impair the growth of both preneoplastic 
and tumor cells in medulloblastoma, inducing them to 
undergo a DNA damage response and apoptosis. These 
effects were observed both in a mouse in vivo model of 
medulloblastoma and in human medulloblastoma cells, 
and resulted in increased survival in the mouse model, 
while Gmnn deficient medulloblastoma cells were 
also sensitized to treatment with the Topo IIα inhibitor 
etoposide. As anticancer agents targeting Gmnn become 
available, our work here suggests they may have utility in 
combination chemotherapies targeting medulloblastoma.
MATERIALS AND METHODS
Human tumor expression
Comparison of Gmnn expression in normal 
cerebellum versus in medulloblastoma tumors used the 
R2: MegaSampler (hgserver1.amc.nl/cgi-bin/r2/main.cgi). 
Data platform is u133p2 [HG-U133_Plus_2] Affymetrix 
Human Genome U133 Plus 2.0 Array, MAS5.0 with 
normalization applied by R2) 2log expression data was 
compared for normal cerebellum (sample accession: Roth; 
n=9; GSE3526) versus four sets of medulloblastoma 
samples (Gilbertson, n=76, GSE37418; Pfister; n=73, 
GSE49243; Delattre, n=57; Kool, n=62, GSE10327).
Mouse strains and animal husbandry
Animal studies were conducted under protocols 
approved by the Washington University Institutional 
Animal Care and Use Committee. Gmnn conditional 
knockout mice (CSD24729) were purchased from 
the Knockout Mouse Project (KOMP). This targeted 
Gmnn allele contains a splice acceptor-βgeo-polyA 
sequence flanked by FRT sites (permitting excision 
by FLPe recombinase) inserted into intron 3 and loxP 
sites flanking exon 4 (permitting excision of exon 4 by 
Cre recombinase). Prior to FLPe excision of the splice 
acceptor-βgeo-polyA sequence, the targeted allele is 
predicted to be a null allele of Gmnn. Excision by FLPe 
recombinase results in a targeted (floxed) allele that 
generates a wild-type mRNA. This floxed allele can be 
converted to a null allele in the presence of Cre, which 
excises exon 4. C57BL/6-Tg(Neurod2-Smo*A1)199Jols/J 
(Jax 008831) and B6.Cg-Tg(Nes-Cre)1Kln/J (Jax 003771) 
mice were obtained from Jackson laboratories. 
Brain isolation, sectioning and immunohisto-
chemistry
 Mice were euthanized by cardiac perfusion 
after anaesthesia according to institutionally approved 
protocols. Brains were processed overnight in 4% 
paraformaldehyde and embedded in paraffin, and matched 
5 µm para-sagittal sections for each genotype were 
processed for immunohistochemistry (IHC) or stained 
with hematoxylin and eosin. IHC was as previously 
described [29] using the primary antibodies indicated, and 
slides were processed for Streptavidin-Peroxide detection 
using the Invitrogen Histostain-SP kit Cat No. #95-9943 
LAB-SA detection system, following the manufacturer’s 
protocol. 
Immunocytochemistry
Cells were fixed using 4% paraformaldehyde, 
washed with PBS containing 0.1% TritonX-100, blocked 
with PBS containing 1% donkey serum, 1% BSA and 
0.1% TritonX-100, and incubated with the respective 
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primary antibodies overnight at 4°C. The next day, the 
slides were washed as above, and secondary antibody 
staining was performed along with DAPI staining. The 
slides were mounted using Prolong Gold anti-fade (Life 
Technologies: P36931) and imaged using a confocal 
microscope, with all images taken at 20X magnification. 
Antibodies
Primary antibodies used for IHC, 
Immunocytochemistry, or Western blotting were 
Gmnn: sc-13015 (Santa Cruz), Ki67: MA1-90584 
(ThermoFisher), Cleaved Caspase-3: #9661 (Cell 
Signaling), Cyclin D1: #134175 (Abcam), p27Kip1: 
#32034 (Abcam), Phospho-histone H3: 06-570 
(Millipore), γH2AX : 05-636 (Millipore); total CHK2: 
#2662 (Cell Signaling Technology); Phospho-(T68) 
CHK2: BS4043 (Bioworld); Phospho-CHK1: #2341 
(Cell Signaling Technology); Total CHK1: #2360 (Cell 
Signaling Technology); γTubulin: ab16504 (Abcam), 
GAPDH: G9545 (Sigma Aldrich). 
qRTPCR and immunoblotting
Total RNA was extracted with the Clontech 
Nucleospin RNA extraction kit (#740955.250), using 
the manufacturer’s protocol. cDNA was synthesized 
using the Bio Rad iScript Reverse Transcriptase 
Supermix (#170-8841), followed by quantitative 
RT-PCR analysis using the Fast SYBR green mix 
from Applied Biosystems (#4385612), as previously 
described [34]. Primers used were: mouse Gmnn 
(F- GCAGTACATGGCGGAGGTAATC and R- 
GCTCCTGAGTCTTCCAGTTCTG), mouse α-Actin 
(F- CATTGCTGACAGGATGCAGAAGG and 
R- TGCTGGAAGGTGGACAGTGAGG), human 
Gmnn (F- CAGCCTTCTGCATCTGGATCTC and 
R- CCAGGGCTGGAAGTTGTAGATG), human 
GAPDH (F- GTCTCCTCTGACTTCAACAGCG 
and R- ACCACCCTGTTGCTGTAGCCAA), human 
α-Actin (F- CACCATTGGCAATGAGCGGTTC and 
R- AGGTCTTTGCGGATGTCCACGT). Protein lysate 
preparation and Western blotting was performed as 
previously described [30].
Cell culture and siRNA transfection
The Daoy (ATCC HTB-186) cell line was grown 
in 10% FBS containing DMEM medium. Lipofectamine 
RNAi max reagent from Thermo Fisher Scientific 
was used for siRNA transfections following the 
manufacture’s protocol. siRNA sequences are: siGem-2: 
AACUUCCAGCCCUGGGGUUAUUU [10], siGem-6: 
Target sequence GAAUAGUUCUGUCCCAAGA 
(siGENOME Human Gmnn Dharmacon), siGAPDH: 
UGGUUUACAUGUUCCAAUA (siGENOME Gapdh 
control Dharmacon).
Growth curve analysis
Cells were counted and seeded at 600,000 cells/
ml on Day 0 and transfected 24 hours later following the 
methods described in the earlier section. The cell numbers 
in each condition were counted and plotted on the growth 
curve.
FACS analysis
1 million cells from each condition were pelleted, 
washed with PBS (without calcium and magnesium), re-
suspended in FACS buffer (PBS plus 3% FBS, 0.04% 
Na-Azide and 1mM EDTA), and fixed by adding drops 
of ice cold 70% ethanol. The cells were stained with 1mg/
ml propidium iodide (P4864; Sigma; 400µl) in 10 mls of 
PBS plus RNase A (500µl). Single cell suspensions of 1 
million cells per condition were used for FACS analysis, 
with propidium iodide staining as a measure for DNA 
content and cell cycle analysis was performed using FloJo 
software. 
Cell cycle synchronization with Hydroxyurea
Daoy cells were counted and seeded at 600,000 
cells/10 cm dish. 24 hours later cells were transfected 
with siRNAs targeting Gmnn (siGem-2 and siGem-6) 
or Gapdh as a control, using Lipofectamine RNAi max 
transfection protocol (Thermo Fisher). 25 nM of each 
siRNA was used. 12 hours later the cells were treated with 
2 mM hydroxyurea (Sigma Aldrich H8627), to arrest the 
cells in the G1 phase of cell cycle, after [85]. After 14 hrs. 
of hydroxyurea treatment, cells were thoroughly washed 
with DMEM +10% FBS medium to remove any residual 
hydroxyurea, and were pelleted for propidium iodide 
staining and FACS analysis 48 hours after the HU release. 
Etoposide treatment. 100nM final etoposide (E1383; 
Sigma Aldrich) dose was used in treating Daoy cells in 
comparison with a DMSO only treatment control. For 
ICC, positive control cells for γH2AX staining were 
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